Interviews

Antimicrobial Resistance
0 The ASPECT-NP study, rationale, results and repercussions – an interview with Igancio Martin-Loeches and Marin Kollef

ECCMID 2019 saw the first presentation of the results from ASPECT-NP, a randomized, multi-center Phase III trial evaluating Merck’s ZERBAXA® (ceftolozane–tazobactam) for the treatment of patients with ventilated nosocomial pneumonia. In light of this we spoke to investigators Marin Kollef and Ignacio Martin-Loeches about the rationale behind this trial, its design and the key findings.

1 2 3 8